| Huang Z et al20) | 1. Comprehensive symptoms score | 1) 14.17±3.44→4.33±1.72(p<0.01)/14.28±3.36→7.46±1.84(p<0.01) 2) Comparison(I/C): p<0.01 |
| 2. VAS | 1) 6.37±1.64→3.04±1.09(p<0.01)/6.12±2.06→4.21±0.94(p<0.01) 2) Comparison(I/C): p<0.01 |
| 3. Efficacy rate & Cure rate | 1) 88.9%(16/18)/66.7%(12/18) & 44.4%(8/18)/27.8%(5/18) 2) Comparison(I/C): p<0.05 & p<0.05 |
| Man PL21) | Degree of improvement | Moderate to marked: 88%(36/41) |
| Zhang WW et al22) | 1. VAS | 1) 7.03±1.71→2.57±1.25(p<0.05)/6.93±1.55→3.67±1.65(p<0.05) 2) Comparison(I/C): p<0.05 |
| 2. SAS | 1) 63.47±8.19→46.27±7.60(p<0.05)/65.50±8.21→55.23±8.02(p<0.05) 2) Comparison(I/C): p<0.05 |
| 3. Chinese medicine symptom score | 1) 13.97±3.54→5.20±2.47(p<0.05)/15.00±3.11→6.83±2.79(p<0.05) 2) Comparison(I/C): p<0.05 |
| 4. Blood test (β-EP§, SPrr, 5HT¶) | 1) β-EP (Comparison(I/C): p<0.05)103.57±18.37→230.63±27.35(p<0.05)/111.70±21.62→183.03±21.90(p<0.05)2) SP (Comparison(I/C): p<0.05)541.13±54.56→285.80±53.71(p<0.05)/546.87±82.72→336.07±50.43(p<0.05)3) 5HT (Comparison(I/C): p<0.05)32.37±4.43→45.93±4.91(p<0.05)/31.40±4.59→37.93±3.50(p<0.05) |
| 5. Efficacy rate | 1) 93.3%(28/30)/83.3%(25/30) 2) Comparison(I/C): p<0.05 |
| Chen ZM et al23) | 1. VAS** | 1) 7.58±1.73→1.18±1.13(p<0.05)/7.42±1.65→2.87±1.42(p<0.05) 2) Comparison(I/C): p<0.05 |
| 2. Comprehensive symptoms score | 1) 17.56±2.11→2.11±1.56(p<0.01)/17.38±2.21→6.76±1.87(p<0.01) 2) Comparison(I/C): p<0.05 |
| 3. Efficacy rate | 1) 90.6%(48/53)/72.0%(36/50) 2) Comparison(I/C): p<0.05 |
| Wu MM et al24) | 1. SF-MPQ†† (VAS, PRI‡‡, PPI§§) | 1) VAS (Comparison(I/C): p<0.05) 6.46±1.55→2.25±0.49(p<0.05)/6.31±1.54→3.00±0.46(p<0.05)2) PRI (Comparison(I/C): p<0.05) 5.90±2.22→2.22±0.58(p<0.05)/5.78±2.08→3.26±0.77(p<0.05)3) PPI (Comparison(I/C): p<0.05) 2.29±0.75→0.60±0.30(p<0.05)/2.39±0.72→0.92±0.41(p<0.05) |
| 2. Chinese medicine symptom score | 1) 15.60±3.78→4.56±1.97(p<0.05)/15.76±4.10→6.60±3.06(p<0.05) 2) Comparison(I/C): p<0.05 |
| 3. PGICrrrr | 1) 4.45±0.72→2.89±0.70(p<0.05)/4.39±0.86→3.72±0.61(p<0.05) 2) Comparison(I/C): p<0.05 |
| 4. Comprehensive symptoms score | 1) 13.00±3.66→4.35±1.28(p<0.05)/12.77±4.00→7.02±1.67(p<0.05) 2) Comparison(I/C): p<0.05 |
| 5. Blood test (IL¶¶-6, TNF***-α, VIP†† † , β-EP) | 1) IL-6 (Comparison(I/C): p<0.05) 27.79±5.67→22.11±4.56(p<0.05)/27.20±5.88→25.53±4.44(p<0.05)2) TNF-α (Comparison(I/C): p<0.05) 40.05±9.13→27.96±8.78(p<0.05)/40.19±7.64→32.94±7.92(p<0.05)3) VIP (Comparison(I/C): p<0.05) 473.49±45.57→331.22±43.71(p<0.05)/471.55±50.14→398.44±45.63(p<0.05)4) β-EP (Comparison(I/C): p<0.05)110.35±15.97→187.35±11.08(p<0.05)/109.30±13.30→147.56±12.67(p<0.05) |
| Peng YY et al25) | 1. Efficacy rate & Cure rate | 93.5%(43/46)/65.0%(26/40) & 60.9%(28/46)/22.5%(9/40) 2) Comparison(I/C): p<0.01 & p<0.01 |
| 2. Frequency of attacks | 1) 10.26±0.12→2.06±0.15(p<0.01)/9.45±0.07→4.15±0.26(p<0.01) 2) Comparison(I/C): p<0.01 |
| 3. Recurrence rate (3 months F/U‡‡‡) | 1) 11.6%(5/43)/53.8%(14/26) 2) Comparison(I/C): p<0.01 |
| Yang JX et al26) | 1. Efficacy rate & Cure rate | 1) 100%(30/30)/96.7%(29/30) & 76.7%(23/30)/63.3%(19/30) 2) Comparison(I/C): p>0.05 & p<0.01 |
| 2. PRI | Comparison(I/C): p<0.05 (F/U 2 and 6months) |
| 3. HAMD§§§ | 1) 17.3±3.9→8.6±3.9(p<0.01)→(F/U 6months) 9.0±3.9(p<0.01*)/18.1±3.6→10.6±6.9(p<0.01)→(F/U 6months) 13.0±6.6(p<0.01*) 2) Comparison(I/C): p<0.05 (F/U 2 and 6months) |
| 4. LSIrrrrrr-B | 1) 7.29±2.14→13.13±2.83(p<0.05)/7.76±2.01→9.95±2.30(p<0.05) 2) Comparison(I/C): p<0.05 |
| Gao J et al27) | 1. Pain (VAS, Headache(%), Generalized body pain(%)) | 1) VAS4.3±4.1→3.5±4.0(p<0.05)→(F/U 6weeks) 2.6±3.1(p<0.05, <0.05rrrrrr)/4.1±3.7→3.7±3.8→(F/U 6weeks) 4.0±3.52) Headache58.06%(36/62)→19.35%(12/62) (p<0.05)→(F/U 6weeks) 22.58%(14/62)(p<0.05)/62.96%(34/54)→57.41%(31/54)→ (F/U 6weeks) 55.56%(30/54)3) Generalized body pain51.61%(32/62)→24.19%(15/62)(p<0.05)→ (F/U 6weeks) 16.13%(10/62)(p<0.05, <0.05rrrrrr)/62.96%(34/54)→53.70%(29/54)→(F/U 6weeks) 57.41%(31/54) |
| 2. Cognitive function evaluation (MMSE****, Tracing score, Memory score, TMT†††† -A score, TMT-B score, VFT‡‡‡‡ score) | 1) MMSE21.5±6.2→24.3±7.6(p<0.05)→(F/U 6weeks) 27.1±7.9(p<0.05, <0.05¶¶¶)/20.3±5.9→21.5±6.8→(F/U 6weeks) 21.1±7.52) Tracing score29.9±5.5→33.4±6.9(p<0.05)→(F/U 6weeks) 34.1±7.3(p<0.05)/30.1±6.6→28.6±5.8→(F/U 6weeks) 29.5±7.13) Memory score12.8±4.7→14.4±5.1(p<0.05)→(F/U 6weeks) 16.3±6.0(p<0.05, <0.05¶¶¶)/11.6±4.4→12.9±4.2→(F/U 6weeks) 13.1±5.34) TMT-A score47.5±8.7→44.1±10.2(p<0.05)→(F/U 6weeks) 40.2±9.1(p<0.05, <0.05¶¶¶)/48.1±9.3→46.9±8.5→(F/U 6weeks) 49.0±10.55) TMT-B score87.3±14.2→81.4±15.3(p<0.05)→(F/U 6weeks) 80.1±16.7(p<0.05)/88.2±17.2→87.1±16.9→(F/U 6weeks) 87.6±15.36) VFT score11.3±4.3→13.4±5.2(p<0.05)→(F/U 6weeks) 14.3±4.9(p<0.05)/10.8±3.8→9.7±4.6→(F/U 6weeks) 11.1±5.8 |
| 3. SF-36§§§§ | 1) Role emotional46.3±9.6→63.1±11.2(p<0.05)→(F/U 6weeks) 64.5±12.1(p<0.05)/42.8±8.8→46.9±9.1→(F/U 6weeks) 48.2±10.52) Vitality46.9±9.5→47.4±7.9→(F/U 6weeks) 60.7±8.8(p<0.05, <0.05¶¶¶)/48.2±8.7→46.4±9.4→(F/U 6weeks) 49.8±10.23) General health43.1±7.7→56.9±8.1(p<0.05)→(F/U 6weeks) 53.6±6.0(p<0.05)/42.8±6.3→45.7±7.1→(F/U 6weeks) 40.9±6.64) Body pain41.9±8.7→58.1±9.2(p<0.05)→(F/U 6weeks) 64.5±8.9(p<0.05, <0.05¶¶¶)/43.7±8.3→44.1±7.6→(F/U 6weeks) 47.2±6.85) Physical function42.8±7.4→44.6±8.3→(F/U 6weeks) 46.2±9.1/44.2±6.9→46.9±7.8→(F/U 6weeks) 43.8±6.46) Role physical63.3±8.3→78.8±9.2(p<0.05)→(F/U 6weeks) 64.9±8.5(p<0.05¶¶¶)/60.4±9.7→65.1±6.7→(F/U 6weeks) 60.2±11.27) Social function60.7±9.1→58.9±10.6→(F/U 6weeks) 62.7±11.3/57.9±8.4→61.1±8.2→(F/U 6weeks) 63.3±7.38) Mental health44.9±6.9→50.2±7.8(p<0.05)→(F/U 6weeks) 58.8±9.1(p<0.05, <0.05¶¶¶)/43.5±7.9→43.6±9.6→(F/U 6weeks) 42.7±10.6 |
| Sun SZ et al28) | Efficacy rate & Cure rate | 1) 100.0%(26/26)/80.8%(21/26) & 84.6%(22/26)/34.6%(9/26) 2) Comparison(I/C): p<0.05 & p<0.01 |
| Sert HY et al29) | VAS | 10→0 (after 6weeks Tx and lasts until the end of 6 months) |
| Zhang XY30) | 1. Efficacy rate & Recovery (cure + marked improvement) rate | 1) 95.6%(43/45)/75.6%(34/45) & 80.0%(36/45)/48.9%(22/45) 2) Comparison(I/C): p<0.05 & p<0.05 |
| 2. 6-point evaluation | 1) 3-4→0-1/3-4→1-3 2) 2) Comparison(I/C): p<0.05 |
| Mishra D et al31) | Patient statement pain level (10 points) | 12/10→2/10 |
| He L et al32) | 1. VAS | 1) 6.38±2.26→2.56±2.18(p<0.01)/5.97±1.40→3.97±3.10(p<0.01) 2) Comparison(I/C): p<0.05 |
| 2. Chinese medicine symptom score | 1) 15.94±3.95→4.47±4.27(p<0.01)/15.41±4.15→6.97±4.03(p<0.01) 2) Comparison(I/C): p<0.05 |
| 3. Efficacy rate (Mann-Whitey test) | 1) 37.19/26.65 2) Comparison(I/C): p<0.05 |
| Zhang YP et al33) | 1. Efficacy rate | 1) 90.9%(30/33)/75.9%(22/29) 2) Comparison(I/C): p<0.05 |
| 2. VAS | 1) 5.12±1.12→1.12±0.12(p<0.001)→(F/U 3months) 1.41±0.47(p<0.01)/4.98±1.21→2.01±0.59(p<0.001)→(F/U 3months) 2.58±0.94(p<0.01) 2) Comparison(I/C): p<0.05(end of treatment and F/U) |
| 3. Frequency of attacks | 1) 9.64±2.81→3.89±1.24(p<0.001)→(F/U 3months) 4.41±1.07(p<0.01)/9.56±2.94→5.51±3.09(p<0.001)→(F/U 3months) 6.22±2.56(p<0.01) 2) Comparison(I/C): p<0.05(end of treatment and F/U) |